Company
Every investor coverage indicates participated in a round Annals of Allergy, Asthma, and Immunology raised.
Companies Annals of Allergy, Asthma, and Immunology acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Robert A. Wood | Associate Editor (former) | Brandon Capital portfolio |
Stories naming Annals of Allergy, Asthma, and Immunology. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Aravax clears its US FDA application to trial its peanut-allergy immunotherapy PVX108 in Phase 2 studies across two countries, and adds a prominent food-allergy paediatric specialist to its scientific advisory board.